dc.contributor.author |
Llaro-Sánchez, Manuel K. |
|
dc.contributor.author |
Guzman-Ramos, Ronald N. |
|
dc.contributor.author |
Gamarra-Villegas, Bernardo E. |
|
dc.contributor.author |
Campos-Correa, Karen E. |
|
dc.date.accessioned |
2021-10-04T23:01:05Z |
|
dc.date.available |
2021-10-04T23:01:05Z |
|
dc.date.issued |
2021 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/9976 |
|
dc.description.abstract |
Objective: To explore the therapeutic regimen and factors associated with mortality in patients with severe COVID-19 infection treated at the Hospital Nacional Alberto Sabogal Sologuren in 2020. Materials and methods: An observational, case-control, analytical and prospective study conducted in patients with severe COVID-19 infection at hospital admission between June and September 2020. The study population was classified into two groups: case group (61 deceased patients) and control group (60 discharged patients). Data were analyzed using Stata statistical software. Bivariate and multivariate logistic regression analyses were performed with a 95 % confidence level. Results: As for patients with severe COVID-19 infection, ages older than 60 years are associated with mortality (p = 0.035; OR = 2.21; CI: [1.05 – 4.63]). Different therapeutic regimens were included in the research: patients who received high-dose methylprednisolone had more probability of dying compared to those who received other corticosteroids (p = 0.001; adjusted OR = 5.18; CI: [1.94 – 13.83]). Patients who were treated with azithromycin for more than five days had more probability of dying compared to those that took it for fewer days (p = 0.000; adjusted OR = 7.14; CI: [2.22 – 22.99]). The multivariate model showed a 73.06 % predictive probability of mortality for patients with severe COVID-19 infection. Conclusions: The therapeutic regimens that include the administration of high-dose methylprednisolone and azithromycin for more than five days increase the probability of dying in patients with severe COVID-19 infection. Furthermore, ages over 60 years were associated with mortality in the patients who participated in the study |
en_US |
dc.description.abstract |
Objetivo: Explorar el esquema terapéutico y factores asociados a mortalidad en pacientes con un cuadro severo de COVID-19 atendidos en el Hospital Nacional Alberto Sabogal Sologuren en 2020. Materiales y métodos: Estudio observacional, analítico de caso-control y prospectivo. Fueron incluidos los pacientes que ingresaron al hospital con un cuadro severo de COVID-19 entre junio a septiembre de 2020 y fueron clasificados en dos grupos: el grupo caso (61 pacientes fallecidos) y el grupo control (60 sobrevivientes que recibieron el alta hospitalaria). Los datos fueron analizados en el software estadístico Stata(R) y se realizó análisis bivariado y multivariado con regresión logística, nivel de confianza del 95 %. Resultados: En pacientes con cuadro severo de COVID-19, la edad mayor de 60 años está asociada a la mortalidad (p=0,035; OR=2,21 IC: [1,05-4,63]). Los esquemas terapéuticos fueron variados, los participantes que recibieron metilprednisolona a dosis altas tuvieron mayor probabilidad de morir en comparación a los que recibieron otros corticoides (p=0,001; OR ajustado=5,18 IC: [1,94-13,83]). El tratamiento con azitromicina por más de cinco días incrementa la probabilidad de fallecer en comparación a los que la tomaron por menos días (p=0,000; OR ajustado=7,14 IC: [2,22-22,99]). El modelo multivariado tenía una probabilidad predictiva de mortalidad de 73,06 % para los pacientes con cuadro severo de COVID-19. Conclusiones: Los esquemas terapéuticos que incluyen administración de metilprednisolona a dosis altas y azitromicina por más de 5 días incrementan la probabilidad de fallecer en los pacientes con una presentación severa de COVID-19. Además, la edad mayor a 60 años estuvo asociada a la mortalidad en los pacientes analizados en el estudio |
es_PE |
dc.language.iso |
spa |
|
dc.publisher |
Facultad de Medicina Humana. Universidad de San Martín de Porres |
|
dc.relation.ispartofseries |
Horizonte Médico |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
Coronavirus infections |
en_US |
dc.subject |
Severe acute respiratory syndrome |
en_US |
dc.subject |
Therapeutics |
en_US |
dc.subject |
Adrenal cortex hormones |
en_US |
dc.subject |
Mortality |
en_US |
dc.subject |
Infecciones por coronavirus |
es_PE |
dc.subject |
Síndrome respiratorio agudo grave |
es_PE |
dc.subject |
Terapéutica |
es_PE |
dc.subject |
Corticoesteroides |
es_PE |
dc.subject |
Mortalidad |
es_PE |
dc.title |
Esquemas terapéuticos y factores asociados a la mortalidad en pacientes con infección severa de COVID-19 atendidos en Hospital Nacional Alberto Sabogal Sologuren 2020 |
es_PE |
dc.title.alternative |
Therapeutic regimens and factors associated with mortality in patients with severe COVID-19 infection treated at the Hospital Nacional Alberto Sabogal Sologuren, 2020 |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.24265/horizmed.2021.v21n1.07 |
|
dc.relation.issn |
2227-3530 |
|